Simulations Plus, Inc. - SLP STOCK NEWS

Simulations Plus (Nasdaq: SLP) has established a Scientific Advisory Board (SAB) within its DILIsym Services (DSS) division. The SAB will guide the development of RENAsym, a kidney injury quantification software platform. Key members include experts from Rutgers, Georgia University, and UC San Diego. The SAB’s formation follows a decade of success with the DILIsym initiative, which has helped develop the DILIsym software for liver injury assessment. RENAsym version 1A is expected in late 2021, enhancing DSS's capability in kidney safety assessments for drug developers.

Simulations Plus, Inc. (Nasdaq: SLP) successfully launched the 2021 MIDD+ Scientific Conference, a two-day event highlighting customized modeling and simulation for pharmaceutical scientists. Key topics included the drug development process and the integration of machine learning and population PK/PD approaches. Over 1,000 participants registered, featuring speakers from U.S. FDA and international health agencies. The event also focused on gender disparities in science, with awards recognizing outstanding contributions in the field. Simulations Plus continues to lead in providing innovative tools and services for drug development.

Simulations Plus, Inc. (Nasdaq: SLP) announced that CEO Shawn O’Connor will present at Oppenheimer’s 31st Annual Healthcare Conference on March 16, 2021, at 2:30 p.m. ET. The presentation will be webcast live, and one-on-one meetings will also be conducted with CFO Will Frederick. The accompanying slide presentation will be available on the company's Investors page after the event. For more details about the conference, visit the conference website.

Simulations Plus, Inc. (Nasdaq: SLP) has announced a Phase I NIH-funded SBIR grant received jointly with the University of Pittsburgh Drug Discovery Institute. The grant aims to develop a beta version of DILIsym software integrated with UPDDI’s vLAMPS experimental liver model for predicting the safety of large molecules, such as proteins used in new therapies. Success in this phase could lead to a larger Phase II grant for full commercial development.

This collaboration addresses safety concerns related to large molecule therapeutics, enhancing drug development processes.

Simulations Plus, Inc. (Nasdaq: SLP) announced that CEO Shawn O'Connor and CFO Will Frederick will host a fireside chat at the BTIG Virtual Conference on February 18, 2021, at 12:00 p.m. EST. They will also conduct one-on-one meetings throughout the day. A slide presentation will be available on the Company's Investors page afterward. Simulations Plus specializes in simulation and modeling software for pharmaceutical research and development, supporting major pharmaceutical and regulatory agencies worldwide.

Simulations Plus (Nasdaq: SLP) has launched version 9.8.1 of its GastroPlus® software, enhancing its pharmacokinetics modeling capabilities. Key upgrades include improved drug-drug interaction (DDI) models, new options for lung deposition variability, and better data import processes. These advancements aim to streamline regulatory reviews and enhance communication between health authorities and drug sponsors. The updates are expected to expedite the marketing of new drug products, reinforcing GastroPlus as a leading PBPK software platform.

Simulations Plus (Nasdaq: SLP) announced a distribution agreement with Mosim, a premier biopharmaceutical services company in China, to distribute the MonolixSuite™ PK/PD modeling platform. This partnership aims to enhance the understanding and application of pharmacokinetics and pharmacodynamics in China’s pharmaceutical sector, which is experiencing rapid growth. Mosim's extensive industry connections will support the promotion of MonolixSuite, which includes tools such as PKanalix, Monolix, and Simulx. This agreement strengthens Simulations Plus' market presence in the burgeoning Chinese pharmaceutical market.

Simulations Plus, Inc. (Nasdaq: SLP) has entered a distribution agreement with the Institute of Pharmaceutical Sciences (ICF) to enhance marketing and sales support in South America. ICF, a leading pharmaceutical research center, will leverage its expertise and connections to promote Simulations Plus’s products, including GastroPlus® and ADMET Predictor®. This partnership aims to capitalize on the growing $48 billion Latin American generic drug market by advancing model-informed drug development (MIDD) strategies, providing opportunities for research and regulatory interactions.

Simulations Plus, a leader in the pharmaceutical software industry, reported a successful partnership with Makerere University, enhancing its global reach in pharmacokinetic services. This initiative aims to optimize drug development through advanced modeling solutions. The collaboration is expected to significantly bolster the company's influence in academic research.

Furthermore, Simulations Plus continues to expand its client base, attracting more pharmaceutical firms looking to improve their drug pipelines. The stock remains robust, with positive projections for future growth.